Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
79.73%
Operating Margin
76.91%
Net Margin
27.51%
Efficiency Metrics
Revenue per Expense Ratio
4.33
R&D as % of Revenue
0.28%
Earnings Quality
EBITDA Margin
176.24%
Income Tax Rate
18.31%
EPS
2.0900000000
Balance Sheet Analysis
Current Ratio
0.11
Cash Ratio
0.11
Working Capital
$-3.29B
Debt to Equity
5.35
Debt to Assets
79.86%
Equity Ratio
14.92%
Cash Flow Analysis
Operating Cash Flow Ratio
184.63%
Free Cash Flow Ratio
182.61%
CapEx to Revenue
2.02%
Dividends Paid
$182.44M
Stock Buybacks
$29.06M
Total Shareholder Returns
$211.49M
Cash Position Change
151.27%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Detailed Growth Metrics
Core Performance
Revenue
604.00%
Net Income
372.43%
EPS
361.25%
Operating Income
1,065.55%
Operational Efficiency
R&D Expenses
-0.58%
SG&A Expenses
19.61%
Operating Cash Flow
-24.90%
Free Cash Flow
-25.72%
Balance Sheet Health
Assets
-5.80%
Debt
1.73%
Book Value per Share
4.34%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
-11.35%
Shares Outstanding
-4.44%
Long Term Trends
3Y Revenue/Share
659.97%
5Y Revenue/Share
205.24%
3Y Dividend/Share
17.54%
5Y Dividend/Share
3.06%